


Participant flow



Baseline Characteristics

Characteristics	Total (n = 64)	Control group (n = 34)	Intervention group (n = 30)	p-value
Age , mean (SD)	60.1 (12.1)	59.9 (12.2)	60.3 (12.3)	0.883 ^b
Gender (female) , n (%)	42 (65.6)	23 (67.6)	19 (63.3)	0.795 ^c
Highest educational level (EQF^a) , n (%)				0.816 ^d
No education	5 (7.8)	2 (5.9)	3 (10.0)	
EQF level 1	2 (3.1)	1 (2.9)	1 (3.3)	
EQF level 2/3/4	26 (40.6)	16 (47.1)	10 (33.3)	
EQF level 5/6	24 (37.5)	12 (35.3)	12 (40.0)	
EQF level 7	7 (10.9)	3 (8.8)	4 (13.3)	
Hospitalisation type , n (%)				1.000 ^c
Planned	21 (32.8)	11 (32.4)	10 (33.3)	
Unexpected	43 (67.2)	23 (67.6)	20 (66.7)	
Reason for admission , n (%)				0.231 ^d
Treatment	36 (56.3)	19 (55.9)	17 (56.7)	
Examination	11 (17.2)	8 (23.5)	3 (10.0)	
Medication review	6 (9.4)	4 (11.8)	2 (6.7)	
Observation	9 (14.1)	2 (5.9)	7 (23.3)	
Other	2 (3.1)	1 (2.9)	1 (3.3)	
Number of prescribed medicines on admission , median [range]	5 [5-18]	6 [5-18]	5 [5-10]	0.010 ^e
Number of prescribed medicines at discharge , median [range]	8 [5-21]	8 [5-19]	9 [5-21]	0.541 ^e
Number of self-managed medicines during hospitalisation , median [range]	/	/	8 [5-11]	/

^a European Qualifications Framework; Level 1: primary education, Level 2: lower secondary education, Level 3: upper secondary vocational education, level 4: upper secondary education, Level 5: associate's degree, Level 6: bachelor's degree, Level 7: master's degree

^b Independent T-test

^c Fisher's Exact test

^d Pearson Chi-square test

^e Mann-Whitney U test

Outcome measures

Primary outcome: Medication adherence measured by pill counts

- Percentage of medicines to which patients are adherent to (80 – 120% doses taken)

Total (n = 64)	Control group (n = 34)	Intervention group (n = 30)	p-value
66.3% [SD 33.1]	59.1% [SD 32.7]	74.5% [SD 32.21]	0.062*
* Independent T-test			

- Percentage of medicines to which patients were adherent to, classified by ATC 1st level

ATC 1st level	Number of prescribed medicines	% of medicines adherent to (80 – 120% doses taken)	p-value
A Alimentary tract and metabolism	101	60.4%	0.075*
B Blood and blood forming organs	13	69.2%	
C Cardiovascular system	76	71.1%	
G Genito urinary system and sex hormones	14	78.6%	
H Systemic hormonal preparations	39	74.4%	
J Anti-infectives for systemic use	25	68.0%	
L Antineoplastic and immunomodulating agents	17	94.1%	
M Musculoskeletal system	10	60.0%	
N Nervous system	82	56.1%	
R Respiratory system	11	81.8%	
* Chi-squared test			

Adverse Events

There were no adverse events associated with this study.